Werner C Albrich1, Stephan Harbarth2. 1. Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland. Werner.albrich@kssg.ch. 2. Division of Infectious Diseases and Hospital Epidemiology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland. Stephan.harbarth@hcuge.ch.
Abstract
INTRODUCTION: Patients in the intensive care unit (ICU) frequently receive prolonged or even unnecessary antibiotic therapy, which selects for antibiotic-resistant bacteria. Over the last decade there has been great interest in biomarkers, particularly procalcitonin, to reduce antibiotic exposure. METHODS: In this narrative review, we discuss the value of biomarkers and provide additional information beyond clinical evaluation in order to be clinically useful and review the literature on sepsis biomarkers outside the neonatal period. Both benefits and limitations of biomarkers for clinical decision-making are reviewed. RESULTS: Several randomized controlled trials (RCTs) have shown the safety and efficacy of procalcitonin to discontinue antibiotic therapy in patients with severe sepsis or septic shock. In contrast, there is limited utility of procalcitonin for treatment initiation or withholding therapy initially. In addition, an algorithm using procalcitonin for treatment escalation has been ineffective and is probably associated with poorer outcomes. Little data from interventional studies are available for other biomarkers for antibiotic stewardship, except for C-reactive protein (CRP), which was recently found to be similarly effective and safe as procalcitonin in a randomized controlled trial. We finally briefly discuss biomarker-unrelated approaches to reduce antibiotic duration in the ICU, which have shown that even without biomarker guidance, most patients with sepsis can be treated with relatively short antibiotic courses of approximately 7 days. CONCLUSIONS: In summary, there is an ongoing unmet need for biomarkers which can reliably and early on identify patients who require antibiotic therapy, distinguish between responders and non-responders and help to optimize antibiotic treatment decisions among critically ill patients. Available evidence needs to be better incorporated in clinical decision-making.
INTRODUCTION:Patients in the intensive care unit (ICU) frequently receive prolonged or even unnecessary antibiotic therapy, which selects for antibiotic-resistant bacteria. Over the last decade there has been great interest in biomarkers, particularly procalcitonin, to reduce antibiotic exposure. METHODS: In this narrative review, we discuss the value of biomarkers and provide additional information beyond clinical evaluation in order to be clinically useful and review the literature on sepsis biomarkers outside the neonatal period. Both benefits and limitations of biomarkers for clinical decision-making are reviewed. RESULTS: Several randomized controlled trials (RCTs) have shown the safety and efficacy of procalcitonin to discontinue antibiotic therapy in patients with severe sepsis or septic shock. In contrast, there is limited utility of procalcitonin for treatment initiation or withholding therapy initially. In addition, an algorithm using procalcitonin for treatment escalation has been ineffective and is probably associated with poorer outcomes. Little data from interventional studies are available for other biomarkers for antibiotic stewardship, except for C-reactive protein (CRP), which was recently found to be similarly effective and safe as procalcitonin in a randomized controlled trial. We finally briefly discuss biomarker-unrelated approaches to reduce antibiotic duration in the ICU, which have shown that even without biomarker guidance, most patients with sepsis can be treated with relatively short antibiotic courses of approximately 7 days. CONCLUSIONS: In summary, there is an ongoing unmet need for biomarkers which can reliably and early on identify patients who require antibiotic therapy, distinguish between responders and non-responders and help to optimize antibiotic treatment decisions among critically ill patients. Available evidence needs to be better incorporated in clinical decision-making.
Authors: Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper Journal: Clin Infect Dis Date: 2011-03-01 Impact factor: 9.079
Authors: Jens Ulrik Jensen; Lars Heslet; Tom Hartvig Jensen; Kurt Espersen; Peter Steffensen; Michael Tvede Journal: Crit Care Med Date: 2006-10 Impact factor: 7.598
Authors: Thomas C Havey; Robert A Fowler; Ruxandra Pinto; Marion Elligsen; Nick Daneman Journal: Can J Infect Dis Med Microbiol Date: 2013 Impact factor: 2.471
Authors: S Schroeder; M Hochreiter; T Koehler; A-M Schweiger; B Bein; F S Keck; T von Spiegel Journal: Langenbecks Arch Surg Date: 2008-11-26 Impact factor: 3.445
Authors: Carolina F Oliveira; Fernando A Botoni; Clara R A Oliveira; Camila B Silva; Helena A Pereira; José C Serufo; Vandack Nobre Journal: Crit Care Med Date: 2013-10 Impact factor: 7.598
Authors: David F Gaieski; Mark E Mikkelsen; Roger A Band; Jesse M Pines; Richard Massone; Frances F Furia; Frances S Shofer; Munish Goyal Journal: Crit Care Med Date: 2010-04 Impact factor: 7.598
Authors: Alexander Kutz; Eva Grolimund; Mirjam Christ-Crain; Robert Thomann; Claudine Falconnier; Claus Hoess; Christoph Henzen; Werner Zimmerli; Beat Mueller; Philipp Schuetz Journal: BMC Anesthesiol Date: 2014-11-15 Impact factor: 2.217
Authors: Andreas Hohn; Bernhard Heising; Jan-Karl Schütte; Olaf Schroeder; Stefan Schröder Journal: Langenbecks Arch Surg Date: 2016-06-10 Impact factor: 3.445
Authors: Kevin J Downes; Julie C Fitzgerald; Emily Schriver; Craig L K Boge; Michael E Russo; Scott L Weiss; Fran Balamuth; Sherri E Kubis; Pam Tolomeo; Warren B Bilker; Jennifer H Han; Ebbing Lautenbach; Susan E Coffin; Jeffrey S Gerber Journal: J Pediatric Infect Dis Soc Date: 2020-02-28 Impact factor: 3.164
Authors: Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares Journal: Intensive Care Med Date: 2017-07-19 Impact factor: 17.440
Authors: Kevin J Downes; Scott L Weiss; Jeffrey S Gerber; Sarah B Klieger; Julie C Fitzgerald; Fran Balamuth; Sherri E Kubis; Pam Tolomeo; Warren B Bilker; Xiaoyan Han; Irving Nachamkin; Charles Garrigan; Jennifer H Han; Ebbing Lautenbach; Susan E Coffin Journal: J Pediatric Infect Dis Soc Date: 2017-06-01 Impact factor: 3.164